Abstract library

15 results for "Lim".
#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Baudin
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors: Rinke A, ...
#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dieter Hörsch
Authors: Hörsch D, Luppi G, Jehl V, Peeters M, ...
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...
#678 Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide
Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Edward Wolin
#832 The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is considered to be of value not only in diagnosis but also in monitoring the disease response to treatment. However, only a few studies have been published on this issue.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Professor Young Park
Authors: Park Y, Kim S, Lee J, Park S, ...
#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine
#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study
Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Manon A, Wolin E, Chassaing C, Lewis A, ...